scholarly journals Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women

2001 ◽  
Vol 101 (5) ◽  
pp. 447 ◽  
Author(s):  
Silvia MAFFEI ◽  
Silvia DEL RY ◽  
Concetta PRONTERA ◽  
Aldo CLERICO
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Natriuretic Peptides ◽  
Hormone Replacement ◽  
Cardiac Natriuretic Peptides ◽  
Circulating Levels

scholarly journals Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women

2001 ◽  
Vol 101 (5) ◽  
pp. 447-453 ◽  
Author(s):  
Silvia MAFFEI ◽  
Silvia DEL RY ◽  
Concetta PRONTERA ◽  
Aldo CLERICO
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Steroid Hormones ◽  
Natriuretic Peptide ◽  
Natriuretic Peptides ◽  
Hormone Replacement ◽  
Before And After ◽  
Cardiac Natriuretic Peptides ◽  
Circulating Levels

The mechanisms that mediate the cardioprotective action of steroid hormones in postmenopausal women are poorly understood. To study the inter-relationship between female steroid hormones and cardiac natriuretic peptides, plasma levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) were measured in postmenopausal women, both before and after oestrogen replacement therapy. A total of 22 healthy postmenopausal women (mean age 51.9±4.6 years) were enrolled in the study; all had been postmenopausal for at least 1 year and all reported climacteric symptoms accompanied by increased levels of follicle-stimulating hormone (>30m-i.u./ml) and luteinizing hormone (>20m-i.u./ml), and a reduction in oestradiol (<25pg/ml). All women were given hormone replacement therapy with transdermal oestradiol, either patch (50μg/24 h) or gel (1mg/day), cyclically combined with oral dihydrogesterone (10mg/day for 12 days/month, on days 19-30 of the month). ANP and BNP were measured directly in plasma samples with specific and sensitive immunoradiometric assays before and after hormone replacement therapy (transdermal oestradiol combined with oral dihydrogesterone). Body weight, arterial blood pressure and echocardiographic examination values did not change after hormone replacement therapy. As expected, serum oestradiol increased significantly and gonadotropins decreased as an effect of the hormone replacement therapy. On average, both ANP and BNP had increased significantly after 3 months of hormone replacement therapy [ANP: before treatment, 17.6±9.6pg/ml; after, 23.6±5.6pg/ml (P = 0.0173); BNP: before treatment, 12.6±10.2pg/ml; after, 19.8±14.0pg/ml (P<0.0001)]. Our study indicates that hormone replacement therapy for a period of 3 months induces a rise in the circulating levels of cardiac natriuretic hormones in postmenopausal women. Our data also suggest the working hypothesis that cardiac natriuretic peptides may play an important role in mediating the cardioprotective effects of female steroid sex hormones in women throughout life.

The effects of conjugated equine estrogens plus cyclical dydrogesterone on serum lipoproteins and apoproteins in postmenopausal women

1988 ◽  
Vol 117 (3) ◽  
pp. 339-342 ◽  
Author(s):  
C. D. Fletcher ◽  
E. Farish ◽  
M. M. Dagen ◽  
F. Alazzawi ◽  
D. McQueen ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Hdl Cholesterol ◽  
Serum Lipoproteins ◽  
Conjugated Equine Estrogens ◽  
The Individual ◽  
Equine Estrogens

Abstract. erum lipoprotein and apoprotein concentrations were monitored for 24 weeks in 26 postmenopausal women treated with conjugated equine estrogens (0.625 mg/day) with the addition of dydrogesterone (10 mg/day) for the last 12 days of each 28 day cycle. The women had had no previous hormone replacement therapy. The estrogen plus dydrogesterone regimen caused significant (P < 0.05) increases in triacylglycerol and HDL cholesterol concentrations. Both HDL2 and HDL3 cholesterol were increased. There were no other significant changes in lipoprotein concentrations. Both apoprotein AI and apoprotein All concentrations increased significantly (P < 0.05) over the study period. The ratios of apoprotein AI to apoprotein All, apoprotein AI to HDL cholesterol and apoprotein All to HDL cholesterol did not change. At the doses employed in this study, the use of dydrogesterone as a progestogen alters the effects of conjugated equine estrogens on lipoproteins and reinforces the view that the effects of a combined HRT regimen cannot be predicted from a consideration of the effects of the individual components.

Sign in / Sign up

Export Citation Format

Share Document